about
Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugsExpansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experienceAre needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysisHCV epidemiology in high-risk groups and the risk of reinfection.Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic reviewRapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.Infections with spore-forming bacteria in persons who inject drugs, 2000-2009.Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review.Review and meta-analysis of the association between self-reported sharing of needles/syringes and hepatitis C virus prevalence and incidence among people who inject drugs in Europe.Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs.Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs.Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.Comparison of deaths related to Hepatitis C and AIDS in Scotland.Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing.The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.Estimating the variability in the risk of infection for hepatitis C in the Glasgow injecting drug user population.Uptake of paraphernalia from injecting equipment provision services and its association with sharing of paraphernalia among injecting drug users in Scotland.Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.Anthrax infection among heroin users in Scotland during 2009-2010: a case-control study by linkage to a national drug treatment database.Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland.Spore forming bacteria infections and people who inject drugs: Implications for harm reduction.Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.Recent and Rapid Transmission of HIV among People who Inject Drugs in Scotland Revealed through Phylogenetic Analysis.Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in ScotlandImpact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysisA decade of spore-forming bacterial infections among European injecting drug users: pronounced regional variationAssociation between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in ScotlandThe association between alcohol use and hepatitis C status among injecting drug users in GlasgowExploring Associations Between Perceived HCV Status and Injecting Risk Behaviors Among Recent Initiates to Injecting Drug Use in GlasgowEvaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol)Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis
P50
Q24186785-1B8614FE-CF24-408E-857E-AEFD29C0D7D4Q27013482-E023E8E9-BC4B-4B51-AD10-5A8CF8E8C8CEQ28304793-4C704214-6D34-4098-9E83-AC4AAE6BE2ABQ30245241-9CD220B9-FFB8-4722-99A9-4E3651560596Q30713067-649C9EE0-4604-4721-864D-19E205806A98Q33752193-909D02CE-6EE8-4810-B26B-9C17EC669BF1Q34028058-8789656E-316C-4439-BF5F-0E6B5C5A6B63Q34103196-E7B0F3B1-252E-4DA4-9213-F068DE210758Q34968558-977874CB-A2BC-4924-9842-B9874D47202AQ36570820-69B35F7C-C34C-4BC9-AAE9-CAA5EA597E74Q37812971-163DE444-968F-405E-B3FF-43BB9C565E9DQ38048506-4D080888-D421-4430-90AC-2BD1620C721DQ38677838-C3B7CE3A-7F4B-47D4-8734-AF4C61B5A3EFQ38893360-C7D3E912-B7CC-47E6-8EC9-DBD54C03CAB1Q40048259-C2B30FE1-6F53-420E-8052-C4D6422A98EFQ40069643-B9BF954C-6661-44D0-9FEE-CA01E5F57C1EQ40145593-9F4D8C98-AEBC-48EC-A0FB-076273879C82Q42288989-8E72A9AC-45CA-46CA-B916-C4AC185F9A24Q42602432-01D75EE2-7731-4E3B-94F0-C476F0451DF7Q42642021-5A9D0587-9925-442B-A743-A7D60F2A9835Q42656367-FDC4FD9F-0C7D-4A7A-A8B1-E8948F174582Q42720607-CD52E4E3-27BF-4E91-AE26-6D3D494B21D7Q45109915-3E65098D-76C8-4E45-8037-9595EF7A24EDQ45353941-16FF8158-DBAA-4409-BA32-6F6A7614ECECQ47562018-ED5A5625-0633-456E-A2E6-36FC2B15CDCFQ50135239-8E4C8382-DFA1-493F-808C-0BFB131B5F21Q51739470-4C23E887-4A23-474A-A7B5-E1042850FB8EQ57700820-C81A880F-2FFD-407B-8614-68C995D6C7A3Q57700826-3DD36A73-9A05-4D72-95A4-D1D4F128AB7AQ58598733-EE072104-B353-4983-BA0E-EA09181ED1E5Q59210855-48019735-D43A-457B-A836-2BFF4A784422Q60169652-DB2977C5-A42E-42C9-852E-054BB2D1B246Q60169653-76416696-C050-468F-A4DF-3DBB18283BBAQ60169656-21AA43B7-2091-402E-8EF2-73B526FE6484Q90261320-5FDDE0A7-792D-4ADD-B00A-732459D12F3BQ93075279-BEE983AB-9E69-4BDC-B69F-7A0DE1E81022
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Norah Palmateer
@ast
Norah Palmateer
@en
Norah Palmateer
@es
Norah Palmateer
@nl
Norah Palmateer
@sl
type
label
Norah Palmateer
@ast
Norah Palmateer
@en
Norah Palmateer
@es
Norah Palmateer
@nl
Norah Palmateer
@sl
altLabel
Palmateer N
@en
prefLabel
Norah Palmateer
@ast
Norah Palmateer
@en
Norah Palmateer
@es
Norah Palmateer
@nl
Norah Palmateer
@sl
P106
P21
P31
P496
0000-0003-4493-0173